EMA/506135/2013

European Medicines Agency decision

P/0222/2013

of 16 September 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for vorapaxar (EMEA-000778-PIP02-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0222/2013

of 16 September 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for vorapaxar (EMEA-000778-PIP02-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Merck Sharp & Dohme (Europe), Inc on 3 August 2012 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 9 August 2013, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for vorapaxar, tablet, powder for oral suspension, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for vorapaxar, tablet, powder for oral suspension, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for vorapaxar, tablet, powder for oral suspension, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Merck Sharp & Dohme (Europe), Inc, Clos du Lynx, 5, B-1200 – Brussels, Belgium.

Done at London, 16 September 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/307741/2013 corr

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-000778-PIP02-12

Scope of the application

Active substance(s):

Vorapaxar

Condition(s):

Prevention of arterial thromboembolism

Pharmaceutical form(s):

Tablet

Powder for oral suspension

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Merck Sharp & Dohme (Europe), Inc

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Merck Sharp & Dohme (Europe), Inc submitted for agreement to the European Medicines Agency on 3 August 2012 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 12 September 2012.

Supplementary information was provided by the applicant on 17 May 2013. The applicant proposed modifications to the paediatric investigation plan.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
   - to grant a deferral in accordance with Article 21 of said Regulation,
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population, Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 9 August 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: prevention of arterial thromboembolism

The waiver applies to:

- the paediatric population of less than 3 months of age;
- for powder for oral suspension for oral use;
- on the grounds that the specific medicinal product is likely to be unsafe.

The waiver applies to:

- the paediatric population from birth to less than 18 years of age;
- for tablet for oral use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition: prevention of arterial thromboembolism

2.1.1. Indication(s) targeted by the PIP

Prevention of thromboembolic events in paediatric patients

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 months to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Powder for oral suspension for oral use

2.1.4. Measures

Area	Number of measures	Description
Quality	2	Measure 1) Development of age appropriate oral liquid formulation (powder for oral suspension or solution) to be agreed with the PDCO prior to studies in children. Measure 2) Demonstration of the adequacy of existing measuring syringes or development of a dedicated measuring syringe and generation of data supporting dosing accuracy across full dose range.

Area	Number of measures	Description
		Measure 3) Open-label, single dose randomized, crossover study to evaluate comparative bioavailability of vorapaxar powder for oral suspension for oral use in healthy subjects
Non-clinical	1	Measure 4) Oral toxicity and toxicokinetic study in juvenile rats
Clinical	2	Measure 5) In vitro platelet aggregation study with vorapaxar in paediatric (3 months to less than 18 years) and adult platelets Measure 6) Randomized, open-label, multicentre study to evaluate efficacy, safety and tolerability of vorapaxar versus investigative site standard of care in the prophylaxis of thrombotic complications in infants and toddlers from 3 months of age, children and adolescents with cardiac malformations

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2022
Deferral for one or more measures contained in the paediatric investigation plan:	Yes